Do untreated obstructive sleep apnea and fragmented sleep lower pain thresholds?

Untreated obstructive sleep apnea (OSA) and sleep fragmentation significantly impair restorative sleep recovery, driving physiological changes that lower pain thresholds and elevate clinical pain sensitivity.

Clinical impact on pain thresholds

• Sensitization markers: Polysomnographic markers of OSA, including a high Apnea-Hypopnea Index (AHI) and severe nocturnal hypoxemia, strongly correlate with chronic pain intensity. Quantitative sensory testing (QST) in untreated individuals consistently reveals hyperalgesia and reduced pressure pain thresholds.
• Central processing: Controlled sleep disruption studies show that fragmented sleep facilitates central sensitization, resulting in enhanced temporal summation of pain and impaired descending pain modulation. Reversing this impairment, such as through CPAP therapy, restores sleep continuity and raises pain thresholds back toward baseline.

Mechanistic pathways of hypersensitivity

• Impaired sleep recovery: Sleep fragmentation prevents deep, restorative sleep stages. This disruption alters glutamatergic and orexinergic signaling in central arousal and nociceptive circuits, actively lowering mechanical and thermal pain thresholds.
• Intermittent hypoxia: Cyclic oxygen desaturations trigger oxidative stress and stabilize hypoxia-inducible factor-1 alpha (HIF-1α). This stabilization activates key transcription factors like NF-κB, driving systemic inflammation and neuroinflammation.
• Neuro-immune activation: Activated microglia and recruited macrophages release key proinflammatory cytokines, specifically interleukin-1 beta (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α). These cytokines lower the activation thresholds of peripheral nociceptors—causing hyperalgesic priming—and enhance excitatory synaptic transmission in the spinal dorsal horn.

Bottom line

• Untreated obstructive sleep apnea and fragmented sleep lower pain thresholds through a dual mechanism: sleep recovery failure disrupts central neuromodulatory systems (glutamatergic and orexinergic pathways), while intermittent hypoxia drives inflammatory and neuro-immune-mediated nociceptive sensitization.